11 results
To investigate whether the inhalation of helium during rpimary PCI can reduces the size of myocardial infarction.
The primary objective is to investigate whether helium influences coronary artery circulation in humans undergoing elective percutaneous coronary interventions (PCI).
The primary objective is to investigate the feasibility and the safety of heliox administration, a gaseous mixture of 79% helium en 21% oxygen, for 8 hours in acute ischemic stroke.
The objective of this trial is to investigate the feasibility and safety of helium ventilation post cardiac arrest.
Primary objective: The primary objective is to assess the efficacy and safety of nemolizumab (CD14152) after a 16-week treatment period in adult and adolescent subjects with moderate-to-severe atopic dermatitis (AD) not adequately controlled with…
Primary Objective(s) (Cohort 1):* To demonstrate that CFZ533 600 mg and/or 300 mg bi-weekly (Q2W), subcutaneous (SC), is non-inferior to a tacrolimus-based regimen with respect to the proportion of patients who experience composite efficacy failure…
Secondary objectiveTo assess the safety and tolerability of the investigational treatments in patients with moderate to severe hidradenitis suppurativa (HS) by:• Number and severity of AEs • Physical examination, vital signs, safety laboratory…
The purpose of this trial is to- determine the dose-response of iscalimab in a population of patients with moderate-to-severe Sjögren*s Syndrome (SjS), defined by ESSDAI >=5and ESSPRI >=5 (Cohort 1)- evaluate the preliminary efficacy…
The primary objective of this study is to evaluate the safety and tolerability of iscalimab at two dose levels (600 mg and 300 mg) in patients withSjögren*s Syndrome, who participated in the TWINSS core study,CCFZ533B2201.Secondary…
The primary objective is to assess the long-term safety of nemolizumab (CD14152) in adult and adolescent subjects with moderate-to-severe atopic dermatitis (AD).The secondary objective is to assess the long-term efficacy of nemolizumab (CD14152) in…
This study will allow the assessment of the ability of CFZ533 to replace calcineurin inhibitors (CNIs) in terms of anti-rejection efficacy, while providing potentially better renal function with an expected similar safety and tolerability profile.…